Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Polycystic Ovary Syndrome (PCOS) Drugs Market by Type (Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agent, Antidepressant, Anti-Obesity), By Application (Hospital, Clinic) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Polycystic Ovary Syndrome (PCOS) Drugs Market by Type (Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agent, Antidepressant, Anti-Obesity), By Application (Hospital, Clinic) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 310567 4200 Pharma & Healthcare 377 213 Pages 4.5 (38)
                                          

Industry Growth Insights published a new data on “Polycystic Ovary Syndrome (PCOS) Drugs Market”. The research report is titled “Polycystic Ovary Syndrome (PCOS) Drugs Market research by Types (Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agent, Antidepressant, Anti-Obesity), By Applications (Hospital, Clinic), By Players/Companies Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Sanofi”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Polycystic Ovary Syndrome (PCOS) Drugs Market Research Report

By Type

Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agent, Antidepressant, Anti-Obesity

By Application

Hospital, Clinic

By Companies

Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Sanofi

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

213

Number of Tables & Figures

150

Customization Available

Yes, the report can be customized as per your need.


Global Polycystic Ovary Syndrome (PCOS) Drugs Industry Outlook


Global Polycystic Ovary Syndrome (PCOS) Drugs Market Report Segments:

The global Polycystic Ovary Syndrome (PCOS) Drugs market is segmented on the basis of:

Types

Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agent, Antidepressant, Anti-Obesity

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Sanofi
  2. Novartis AG
  3. Teva Pharmaceutical Industries Limited
  4. Addex Therapeutics Ltd.
  5. BIOCAD
  6. Merck KGaA
  7. AstraZeneca plc.
  8. Bristol Myers Squibb Co.
  9. Ferring Pharmaceuticals, Inc.
  10. Crinetics Pharmaceuticals, Inc.
  11. Sanofi

Global Polycystic Ovary Syndrome (PCOS) Drugs Market Overview


Highlights of The Polycystic Ovary Syndrome (PCOS) Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Oral Contraceptives
    2. Antiandrogens
    3. Insulin-Sensitizing Agent
    4. Antidepressant
    5. Anti-Obesity
  1. By Application:

    1. Hospital
    2. Clinic
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Polycystic Ovary Syndrome (PCOS) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Polycystic Ovary Syndrome (PCOS) Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Polycystic ovary syndrome (PCOS) is a condition that affects the way a woman's ovaries function. The most common symptoms of PCOS are irregular periods, excess hair on the face and body, and difficulty getting pregnant. Some women with PCOS also have problems with their weight or moods. There is no one specific drug that can help treat PCOS, but many different medications are available to help manage the condition. Some common drugs used to treat PCOS include birth control pills, insulin-sensitizing agents (such as metformin), and testosterone therapy. It is important to talk with your doctor about which drug may be best for you based on your individual symptoms and health history.

Some of the key players operating in the polycystic ovary syndrome (pcos) drugs market are Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Sanofi.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Polycystic Ovary Syndrome (PCOS) Drugs Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Polycystic Ovary Syndrome (PCOS) Drugs Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Polycystic Ovary Syndrome (PCOS) Drugs Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Polycystic Ovary Syndrome (PCOS) Drugs Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size & Forecast, 2020-2028       4.5.1 Polycystic Ovary Syndrome (PCOS) Drugs Market Size and Y-o-Y Growth       4.5.2 Polycystic Ovary Syndrome (PCOS) Drugs Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 Oral Contraceptives
      5.2.2 Antiandrogens
      5.2.3 Insulin-Sensitizing Agent
      5.2.4 Antidepressant
      5.2.5 Anti-Obesity
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Clinic
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Polycystic Ovary Syndrome (PCOS) Drugs Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 Oral Contraceptives
      9.6.2 Antiandrogens
      9.6.3 Insulin-Sensitizing Agent
      9.6.4 Antidepressant
      9.6.5 Anti-Obesity
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Clinic
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 Oral Contraceptives
      10.6.2 Antiandrogens
      10.6.3 Insulin-Sensitizing Agent
      10.6.4 Antidepressant
      10.6.5 Anti-Obesity
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Clinic
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 Oral Contraceptives
      11.6.2 Antiandrogens
      11.6.3 Insulin-Sensitizing Agent
      11.6.4 Antidepressant
      11.6.5 Anti-Obesity
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Clinic
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 Oral Contraceptives
      12.6.2 Antiandrogens
      12.6.3 Insulin-Sensitizing Agent
      12.6.4 Antidepressant
      12.6.5 Anti-Obesity
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Clinic
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 Oral Contraceptives
      13.6.2 Antiandrogens
      13.6.3 Insulin-Sensitizing Agent
      13.6.4 Antidepressant
      13.6.5 Anti-Obesity
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Clinic
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Polycystic Ovary Syndrome (PCOS) Drugs Market: Competitive Dashboard
   14.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Sanofi
      14.3.2 Novartis AG
      14.3.3 Teva Pharmaceutical Industries Limited
      14.3.4 Addex Therapeutics Ltd.
      14.3.5 BIOCAD
      14.3.6 Merck KGaA
      14.3.7 AstraZeneca plc.
      14.3.8 Bristol Myers Squibb Co.
      14.3.9 Ferring Pharmaceuticals, Inc.
      14.3.10 Crinetics Pharmaceuticals, Inc.
      14.3.11 Sanofi

Our Trusted Clients

Contact Us